Sandoz Strikes $500m Deal For GSK Cephalosporins
Deal To Acquire Cephalosporins Business Reinforces Position In Antibiotics
Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.
You may also be interested in...
With plans to enable genomic surveillance for antimicrobial resistant pathogens using Ares’ next-generation sequencing and bioinformatics technologies, the OpGen subsidiary and Sandoz have shaken hands on an extension to their initial master services agreement.
Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.
Sandoz has shed some light on how it intends to invest €150m into its European antibiotics manufacturing network, while announcing the closure of a plant in Spain to remain “cost-competitive on the global market.”